A preparation method of virus vaccine expressing Plasmodium ovale ama1 protein
A technology of Plasmodium ovale and vaccine, which is applied in the fields of virology and genetic engineering, can solve the problem of no effective vaccine for Plasmodium ovale infection, etc., and achieve the effects of strong humoral immunity and cellular immune response, low price and short production cycle
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0038] Embodiment 1: Preparation of the recombinant vesicular stomatitis virus vaccine of AMA1 protein:
[0039] (1) Construction of pXN2-AMA1 recombinant plasmid: gene synthesis of Plasmodium ovale AMA1 gene (PocGH01_09039800), and insertion of the target gene AMA1 into the G and L restriction enzyme cutting sites of the vesicular stomatitis virus genome through the Xho1 and Nhe1 restriction sites Between points, construct the recombinant VSV genome plasmid VSV-XN2-AMA1, namely pXN2-AMA1;
[0040] (2) Inoculate 5x10 cells in a 10cm cell culture dish 6 BHK-21 cells were incubated with DMEM containing 10% FBS at 37°C, 5% CO 2 cultured in a cell culture incubator;
[0041] (3) After 24 hours, when the cells grow to 80%-90% confluence, the BHK-21 cell culture medium is discarded, and 10 6 The T7 poxvirus of PFU was diluted with 3ml DMEM serum-free medium to infect BHK-21 cells to provide the T7 RNA polymerase required for VSV recombinant virus packaging;
[0042] (4) After 2 ...
Embodiment 2
[0050] Embodiment 2: rVSV-AMA1 immune response comparison
[0051] experiment one)
[0052] Mice immunization: 6-8 week old male BALB / C mice were divided into rVSV-AMA1, AMA1pro and VSV control groups, with 6 mice in each group.
[0053] The recombinant vesicular stomatitis virus rVSV-AMA1 expressing Plasmodium ovale AMA1 obtained in Example 1 of the present invention was treated at week 0 with 10 6 Male BALB / C mice were immunized by intraperitoneal injection of PFU for 6-8 weeks as the rVSV-AMA1 group.
[0054] Purified AMA1 protein was mixed with Freund's adjuvant in equal proportions and injected intraperitoneally with 50 μg. The primary immunization at week 0 and the booster immunization at the third week were used as the AMA1pro group.
[0055] Empty vector virus VSV at week 0 with 10 6 PFU was injected intraperitoneally as a negative control group.
[0056] Experiment (2)
[0057] Detection of specific humoral immune response in mice: After five weeks of immunizatio...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com